Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding

Ítems similars

• Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
  per: Caroti Caroti, et al.
  Publicat: (2023-07-01)
• Plasma levels of direct Xa inhibitors apixaban and rivaroxaban in patients with venous thromboembolism in clinical practice
  per: I. Paskaleva, et al.
  Publicat: (2025-05-01)
• Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study
  per: Majed S. Al Yami, et al.
  Publicat: (2023-08-01)
• Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations
  per: Cyril Leven, et al.
  Publicat: (2023-02-01)
• Hospitalizations for bleeding associated with apixaban versus rivaroxaban according to dose in Medicare beneficiaries
  per: Luke S. Vest, et al.
  Publicat: (2025-09-01)